Dr. Andrew D. Zelenetz

Dr. Andrew D. Zelenetz, MD, PhD, is a medical oncologist with special expertise in lymphoma and former Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center. He is a member of a close-knit, multidisciplinary team dedicated to providing compassionate care to patients with lymphoma. His clinical and research contributions have placed him among the leading figures in the field, with a career spanning drug development, translational research, and national guideline leadership.

Dr. Zelenetz has played a direct role in developing several agents now approved for the treatment of lymphoma, including 131I-tositumomab/tositumomab, bortezomib, and pralatrexate. Through ongoing clinical studies, he continues to evaluate novel combinations of these and other agents. A parallel area of his research focuses on improving the prognostic value of pathology specimens through computer-aided image analysis, with the goal of refining how patient outcomes are predicted and treatment decisions are made. He has published more than 100 papers on lymphoma research in leading journals including Blood, Journal of Clinical Oncology, and Clinical Cancer Research.

Dr. Zelenetz is deeply engaged in national organizations dedicated to lymphoma treatment and research. He serves as chairperson of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network and as vice chairperson of the Lymphoma Core Committee of the Cancer and Leukemia Group B. He is also a member of the scientific advisory board of the Lymphoma Research Foundation, reflecting his broad commitment to advancing both clinical care and laboratory research in lymphoma.